Ignite Creation Date:
2024-05-06 @ 7:34 PM
Last Modification Date:
2024-10-26 @ 3:10 PM
Study NCT ID:
NCT06066216
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-01-23
First Post:
2023-09-27
Brief Title:
Cadonilimab AK104 Plus Chemotherapy in Patients With Recurrent or Advanced Endometrial Cancer
Sponsor:
Fujian Cancer Hospital
Organization:
Fujian Cancer Hospital
Study Overview
Official Title:
Efficacy and Safety of Cadonilimab AK104 Plus Chemotherapy in the Treatment of Recurrent or Advanced Endometrial Cancer a Multicenter Prospective Phase II Trial
Status:
NOT_YET_RECRUITING
Status Verified Date:
2023-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is an open-label multi-center Phase II study of cadonilimab AK104 combined with chemotherapy in patients with recurrent or advanced endometrial cancer The primary objective is to evaluate objective response rate of cadonilimab plus chemotherapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None